Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure
- PMID: 22160655
- PMCID: PMC3297756
- DOI: 10.1007/s00520-011-1336-0
Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure
Abstract
Purpose: To investigate the impact of chemotherapy-induced neurotoxicity on daily activities and quality of life (QoL) of cancer patients.
Methods: QoL of all patients visiting the oncological outpatient ward of the Maxima Medical Centre in the Netherlands from October 2006 until March 2007 treated with taxanes, vinca-alkaloids and/or platinum compounds (n = 88) was compared with the QoL of patients that did not receive these treatments yet (n = 43). Patient-reported neuropathy symptoms were evaluated with the newly developed Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) and the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire.
Results: Patients treated with chemotherapy reported significantly more complaints of neuropathy (p < 0.001) and more paresthesias and dysesthesias in the upper (p < 0.001; p < 0.01) and lower extremities (p < 0.001) compared to those not treated with chemotherapy. They additionally experienced problems with fine motor function (e.g., getting (un)dressed, writing, and picking up small objects). Moreover, cold-induced paresthesias were frequently reported. Overall, patients indicated that their neuropathy had a negative effect on QoL.
Conclusions: The newly developed CINQ and the FACT/GOG-Ntx results suggest a considerable negative impact of patient-reported neuropathy symptoms on daily activities and QoL in cancer patients treated with chemotherapy. However, further validation of the CINQ is needed.
References
-
- Calhoun EA, Welshman EE, Chang CH, Lurain LR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynaecologic Oncologic Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741–748. doi: 10.1111/j.1525-1438.2003.13603.x. - DOI - PubMed
-
- Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, Wieand S, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol. 2006;4:W1–W8.
-
- Almadrones L, Deborah B, Guire M, Walczak J, Colleen M, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology study group. Oncol Nurs Forum. 2004;31:615–623. doi: 10.1188/04.ONF.615-623. - DOI - PubMed
-
- Postma TJ, Heimans JJ, Aaronson NK, Grant R, Huddart R, Maher J, Hildehrand JG, et al. The impact of chemotherapy induced peripheral neuropathy on quality of life. J Neurol Neurosurg Psychiatry. 1999;67:838.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources